Tao H. Zeng

No. 1, Minde Road
Nanchang, 330006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 164 publications

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Published: July 06, 2026

Aptamer-based CRISPR-Cas12a fluorescent biosensors for serum biomarker detection.

Aptamer-based CRISPR-Cas12a fluorescent biosensors for serum biomarker detection.

Journal: The Analyst

Published: July 06, 2026

CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application.

CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: May 26, 2026

Efficacy evaluation of urethral dragging-and-adhesion anastomosis in ileal orthotopic neobladder reconstruction following laparoscopic radical cystectomy: a dual-center retrospective study.

Efficacy evaluation of urethral dragging-and-adhesion anastomosis in ileal orthotopic neobladder reconstruction following laparoscopic radical cystectomy: a dual-center retrospective study.

Journal: Frontiers in surgery

Published: May 07, 2026

Exploring the advantages of mixed reality technology in Robot-assisted laparoscopic partial adrenalectomy.

Exploring the advantages of mixed reality technology in Robot-assisted laparoscopic partial adrenalectomy.

Journal: World journal of surgical oncology

Published: February 24, 2026

Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.

Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.

Journal: Frontiers in immunology

Published: February 23, 2026

Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma.

Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma.

Journal: BMC cancer

Published: January 15, 2026

CRISPR-Cas12a/Cas13a in cancer molecular diagnosis.

CRISPR-Cas12a/Cas13a in cancer molecular diagnosis.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: December 15, 2025

Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.

Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.

Journal: Discover oncology

Published: November 19, 2025

Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.

Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.

Journal: BMC cancer

Published: October 27, 2025

Vitamin D and hypoxia-inducible factors signaling interplay: A hypothesis-driven review of therapeutic strategies for acute cerebral infarction.

Vitamin D and hypoxia-inducible factors signaling interplay: A hypothesis-driven review of therapeutic strategies for acute cerebral infarction.

Journal: Metabolic brain disease

Published: October 05, 2025

PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming.

PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming.

Journal: Cell death & disease

Published: September 10, 2025

Showing 1-12 of 164

Last Updated: 09/26/2026